Margo Roberts
Director/Board Member at UNITY BIOTECHNOLOGY, INC.
Net worth: - $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeffrey Wiezorek | M | 52 |
Appia Bio, Inc.
 Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 years |
| Nathaniel David | M | 56 | 15 years | |
| Keith Leonard | M | 62 | 8 years | |
| David Baltimore | M | 86 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 years |
| Jeenjoo Kang | M | 40 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 years |
| Lynne Sullivan | F | 58 | 4 years | |
| Pin Wang | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 years |
| Edmund Kim | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 years |
| Lili Yang | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | 4 years |
| Stephen Hill | M | 53 | 5 years | |
| Alexander Nguyen | M | 47 | 3 years | |
| Michael Samar | M | 51 | 2 years | |
| Gilmore O’Neill | M | 59 | 4 years | |
| Anirvan Ghosh | M | 60 | 4 years | |
| Dominic Piscitelli | M | 50 | 4 years | |
| Camille Samuels | F | 52 | 9 years | |
| David Georges | M | - | 5 years | |
| William Rieflin | M | 64 | 4 years | |
| Paul Berns | M | 57 | 6 years | |
| James H. Wyckoff | M | 72 |
University of Virginia
| 16 years |
| Daqing Cai | M | 59 |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | - |
| David Moskowitz | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | - |
| Francisco Gimenez | M | - |
Appia Bio, Inc.
Appia Bio, Inc. BiotechnologyHealth Technology Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020. | - |
| Richard D. Goold | M | 64 | 5 years | |
| Harry Harding | M | - |
University of Virginia
| 15 years |
| Antonio Jose Periquet | M | 62 |
University of Virginia
| 13 years |
| Carolyn S. Miles | F | 62 |
University of Virginia
| 15 years |
| Elizabeth L. Anderson | M | 83 |
University of Virginia
| 19 years |
| Przemyslaw Sapieha | M | - | 3 years | |
| Chris McDonald | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Aya Jakobovits | M | 71 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 14 years |
| Arie Belldegrun | M | 74 | 8 years | |
| Christian Homsy | M | 65 | 12 years | |
| Filippo Petti | M | 52 | 4 years | |
| Patrick Jeanmart | M | 51 | 11 years | |
| Ferdinand Hui | M | - |
University of Virginia
| 8 years |
| David Tanen | M | 52 | - | |
| Alexander T. Seals | M | - |
University of Virginia
| 5 years |
| Erin McCormack | F | - |
University of Virginia
| 4 years |
| JJ Kasper | M | - |
University of Virginia
| 8 years |
| Andrew Trees | M | - |
University of Virginia
| 4 years |
| David Lacey | M | 71 | 2 years | |
| McGavock Dickinson Dunbar | M | - |
University of Virginia
| 4 years |
| Francis Teo | M | - |
University of Virginia
| 6 years |
| David Clark | M | 47 |
University of Virginia
| 5 years |
| David Chang | M | 64 | 4 years | |
| Edward Shuman | M | - |
University of Virginia
| 9 years |
| Paul L. Jenkinson | M | 64 | 1 years | |
| David Bonderman | M | 81 | 6 years | |
| Thomas Decarlo | M | - |
University of Virginia
| - |
| Rachel C Cantor | F | - |
University of Virginia
| 4 years |
| Jonathan Chou | M | - |
University of Virginia
| 7 years |
| Howard Hechler | M | - |
University of Virginia
| 4 years |
| Katie Bullard | F | - |
University of Virginia
| 4 years |
| Austine Graff | F | - | 1 years | |
| Maria Koehler | M | 67 | - | |
| Ryan Berg | M | - |
University of Virginia
| 10 years |
| Zachary Bratun Glennon | M | - |
University of Virginia
| 4 years |
| Adam Fassnacht | M | - |
University of Virginia
| 6 years |
| Altaf Bahora | M | - |
University of Virginia
| 12 years |
| John Smalley | M | - |
University of Virginia
| 12 years |
| Neil Carter | M | - |
University of Virginia
| 11 years |
| Scott B Crenshaw | M | - |
University of Virginia
| 6 years |
| Max Leykin | M | - |
University of Virginia
| 5 years |
| Kevin Matthew Mixon | M | - |
University of Virginia
| 4 years |
| Kristina Wilmer | F | - |
University of Virginia
| 7 years |
| Raju S. Kucherlapati | M | 81 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 4 years |
| Steven Ruchefsky | M | 61 | 6 years | |
| Stephen Sherwin | M | 75 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 19 years |
| Joshua Kazam | M | 47 | 8 years | |
| Robin Washington | F | 60 | - | |
| Ian Clark | M | 62 | - | |
| Graham Cooper | M | 54 | 5 years | |
| Heather Turner | F | 51 | 4 years | |
| R. Greer | M | 65 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | 5 years |
| Robert Nelsen | M | 60 | 9 years | |
| Cynthia Butitta | F | 69 | 4 years | |
| Roy Doumani | M | 89 | 6 years | |
| Farah Champsi | F | 62 | 4 years | |
| Franz Humer | M | 76 | 2 years | |
| Kristina Burow | F | 50 | 11 years | |
| Craig S. Edwards | M | - |
University of Virginia
| 5 years |
| Brian Nold | M | - |
University of Virginia
| 8 years |
| Rahul Gorawara | M | - |
University of Virginia
| 5 years |
| Claudine Prowse | M | - | - | |
| Jonathan Peacock | M | 66 | 3 years | |
| Greg Mann | M | - | - | |
| Larry L. Green | M | - |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | - |
| Elizabeth Faust | M | 59 | 2 years | |
| Ran Nussbaum | M | 51 | 4 years | |
| Nitin Chandra | M | - |
University of Virginia
| 9 years |
| Chris Carroll | M | - |
University of Virginia
| 4 years |
| Timothy Moore | M | 62 | 3 years | |
| Christine Cassiano | F | - | 1 years | |
| Evan Cantor | M | - |
University of Virginia
| 4 years |
| Lee Daniel Miller | M | - |
University of Virginia
| 4 years |
| Jehangir Saifullah Khan | M | - |
University of Virginia
| 4 years |
| Mark Christopher Koontz | M | 45 |
University of Virginia
| 4 years |
| Henric Persson | M | - |
University of Virginia
| 2 years |
| Chris Lueck | M | - |
University of Virginia
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 94 | 94.00% |
| Belgium | 6 | 6.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Margo Roberts
- Personal Network
